Get the Stockscreener App
67.01
2.35%
1.54
After Hours:
67.02
0.010
+0.01%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $67.01, with a volume of 7.92M.
It is up +2.35% in the last 24 hours and up +9.98% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$65.47
Open:
$65.79
24h Volume:
7.92M
Relative Volume:
0.66
Market Cap:
$136.88B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
18.81
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+4.98%
1M Performance:
+9.98%
6M Performance:
+10.47%
1Y Performance:
+38.36%
1-Day Range:
$65.13
$67.55
1-Week Range:
$63.36
$68.64
52-Week Range:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
67.01 | 133.74B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,255.40 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.24 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.96 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.55 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.86 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK - Yahoo Finance
Why Bristol Myers Squibb (BMY) Stock Is Up Today - Quiver Quantitative
Bristol-Myers Squibb Co Stock (BMY) Moved Up by 3.06% on Aug 21: Drivers Behind the Movement - TradingKey
BMY|Bristol-Myers Squibb Co|Price:67.010|Chg%:+1.540 - TradingKey
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion? - Yahoo Finance
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb - Pharmaceutical Executive
Chai partners with Bristol Myers Squibb on AI-driven antibody discovery - The Pharma Letter
Paralel Advisors LLC Acquires Shares of 38,091 Bristol Myers Squibb Company $BMY - MarketBeat
104,121 Shares in Bristol Myers Squibb Company $BMY Bought by TrinityBridge Ltd - MarketBeat
OneAscent Financial Services LLC Takes Position in Bristol Myers Squibb Company $BMY - MarketBeat
LaSalle St. Investment Advisors LLC Takes $1.12 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Tocqueville Asset Management L.P. Invests $5.30 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Vise Technologies Inc. Acquires Shares of 141,913 Bristol Myers Squibb Company $BMY - MarketBeat
Bank of New York Mellon Corp Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Allworth Financial LP Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb stock edges higher as AI antibody deal and Q2 earnings support outlook - Ad-hoc-news.de
Hillman Value Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Shares Fall 3.2% -- GF Value Says Still Overvalued - GuruFocus
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement - TradingKey
UBS reiterates Buy on Bristol-Myers Squibb stock, $80 target - Investing.com
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - AOL.com
Chai tees up Bristol Myers Squibb AI antibody discovery collab - Fierce Biotech
UBS reiterates Buy on Bristol-Myers Squibb stock, $80 target By Investing.com - Investing.com Canada
Bristol Myers Squibb stock steadies as FDA approval and Houston expansion reshape outlook - Ad-hoc-news.de
Bristol-Myers Squibb partners with Chai Discovery to leverage AI in developing new therapies - 富途牛牛
Bristol Myers Squibb, Chai Partner on AI Antibody Discovery - Contract Pharma
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery - Business Wire
United Bank Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Johnson Financial Group Inc. Buys Shares of 21,307 Bristol Myers Squibb Company $BMY - MarketBeat
33,580 Shares in Bristol Myers Squibb Company $BMY Acquired by one8zero8 LLC - MarketBeat
Patrick Mauro Investment Advisor INC. Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Knuff & Co LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Edmond DE Rothschild Holding S.A. Acquires Shares of 113,537 Bristol Myers Squibb Company $BMY - MarketBeat
Bell & Brown Wealth Advisors LLC Invests $2.46 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Abacus FCF Advisors LLC Makes New $13.11 Million Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Stock Traders Buy High Volume of Bristol Myers Squibb Call Options (NYSE:BMY) - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Sets New 52-Week HighWhat's Next? - MarketBeat
Bristol-Myers Squibb stock hits 52-week high at 68.1 USD - Investing.com
AstraZeneca Vs. Bristol-Myers Squibb: Who’s The Better Bargain For Investors (NYSE:BMY) - Seeking Alpha
FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb - 巴士的報
FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb – Company AnnouncementFT.com - Financial Times
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma - Yahoo Finance
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - AOL.com
Bristol Myers Squibb to build $2.3B manufacturing campus in Houston - Yahoo Finance
Bristol-Myers Squibb stock holds gains as Zenbexus approval and fresh guidance shape the outlook - AD HOC NEWS
Bristol Myers Squibb Company $BMY Holdings Trimmed by Pzena Investment Management LLC - MarketBeat
Great Lakes Advisors LLC Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Danica Pension Livsforsikringsaktieselskab Buys New Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Diversify Advisory Services LLC Invests $2.33 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):